News about "Teva Pharmaceuticals"

Teva Wins US FDA Approval for Monthly Olanzapine Injection

Teva has announced US FDA approval of WELTRUZA for ER injectable suspension, as the first and only once-monthly subcutaneous injectable polanzapine for adults.

Teva Pharmaceuticals | 12/10/2026 | By News Bureau

Teva Reports Ecopipam Data in Pediatric Tourette Syndrome

Teva Pharmaceuticals has reported new ecopipam data showing clinically meaningful tic reduction in about 70 percent of pediatric Tourette Syndrome patients within 8 weeks.

Teva Pharmaceuticals | 05/10/2026 | By News Bureau

Teva Pharmaceuticals Reports Positive Phase 2a Results for Anti-IL-15 Antibody in Celiac Disease

Teva Pharmaceuticals reports positive phase 2a results for TEV ‘408, an anti-IL-15 antibody that significantly prevented gluten-induced intestinal damage in celiac disease.

Teva Pharmaceuticals | 03/09/2026 | By News Bureau |  107

Teva Pharma and Trump Administration Plan Agreement on Affordable Medicines

Teva Pharma plans an agreement with the Trump Administration to align US Medicaid pricing for select medicines with leading developed markets under the GENEROUS framework.

Teva Pharmaceuticals | 02/09/2026 | By News Bureau

Teva Plans Acquisition of Novel Neuroscience Product

Teva plans to acquire BXCL501, a novel dexmedetomidine sublingual film under the US Food and Drug Administration (FDA) review for potential at-home treatment of acute agitation in adults with schizophrenia or bipolar disorder.

Teva Pharmaceuticals | 01/09/2026 | By News Bureau

Teva Completes Acquisition of Emalex Biosciences

Teva has completed its acquisition of Emalex Biosciences, strengthening its late-stage neuroscience pipeline. The deal supports Teva’s Pivot to Growth strategy.

Teva Pharmaceuticals | 12/06/2026 | By News Bureau |  189

ScinoPharm Wins FDA Approval for Glatiramer Acetate Injection

ScinoPharm Taiwan has received US FDA approval for its Glatiramer Acetate Injection for the treatment of multiple sclerosis, marking a significant milestone as the first and only Taiwanese pharmaceutical company to secure FDA approval for this complex generic, and reinforcing Taiwan’s growing role in the global pharmaceutical supply chain.

Teva Pharmaceuticals | 05/01/2026 | By News Bureau |  234

CCT, Kuehne+Nagel and Teva Prove Ocean Freight Viable for Temperature-Sensitive Pharmaceuticals

Cold Chain Technologies (CCT), a global leader in temperature-controlled packaging, has successfully completed a landmark project with logistics giant Kuehne + Nagel and Teva Pharmaceuticals, demonstrating the viability of ocean freight for high-value, temperature-sensitive pharmaceutical shipments.

Teva Pharmaceuticals | 15/10/2025 | By Dineshwori |  524

Teva Pharmaceuticals Launches First Generic Version of Saxenda in US

The first generic version of Saxenda, Liraglutide injection, is approved for adults with obesity or overweight who have weight-related medical conditions, as well as for paediatric patients aged 12 to 17 years weighing more than 60 kg with obesity.

Teva Pharmaceuticals | 30/08/2025 | By Dineshwori |  912

Global Topical Antibiotics Market Projected to Surpass USD 11 Billion by 2032

The global topical antibiotics market, valued at USD 6.42 billion in 2024, is expected to reach nearly USD 11.20 billion by 2032.

Teva Pharmaceuticals | 14/07/2025 | By Dineshwori |  348